论文部分内容阅读
目的探讨黄芪注射液用于治疗小儿支气管哮喘,对患儿免疫及气道重塑状态的影响。方法选取2011年7月至2013年12月收治的60例支气管哮喘患儿为研究对象,将60例患儿遵循随机分配的原则分为对照组(常规西药治疗组)30例和观察组(常规西药加黄芪注射液治疗组)30例,于治疗7、14 d时对两组患儿的免疫指标:红细胞免疫相关的免疫黏附促进因子(FEER)、免疫黏附抑制因子(FEIR)及辅助T淋巴细胞(Th)1和Th2的细胞百分比;及气道重塑相关血清指标:内皮素(ET)-1、基质金属蛋白酶(MMP)-3、MMP-9及金属蛋白酶组织抑制剂(TIMP)-1进行检测与比较。结果两组治疗后各项指标均好于本组治疗前(P均<0.05)。观察组治疗后7 d与14 d时的Th1及FEER均高于对照组,Th2及FEIR均低于对照组,气道重塑相关血清指标也均显著地低于对照组(P均<0.05)。结论黄芪注射液可有效改善支气管哮喘患儿的免疫及气道重塑状态,对于患儿疾病及机体整体的改善作用较好。
Objective To investigate the effect of astragalus injection on bronchial asthma in children and the immune and airway remodeling in children. Methods Sixty children with bronchial asthma admitted from July 2011 to December 2013 were selected as study objects. Sixty children were randomly divided into control group (conventional western medicine group) 30 cases and observation group Western medicine plus Astragalus injection treatment group) 30 cases, in the treatment of 7,14 d when the two groups of children immune indicators: erythrocyte immune-related immune adhesion molecule (FEER), immune adhesion inhibitor (FEIR) and helper T lymph (Th) 1 and Th2; and serum markers related to airway remodeling: endothelin (ET) -1, matrix metalloproteinase (MMP) -3, MMP-9 and tissue inhibitor of metalloproteinase (TIMP) 1 for testing and comparison. Results After treatment, the indexes in both groups were better than those before treatment in both groups (all P <0.05). Th1 and FEER in observation group were higher than those in control group on the 7th and 14th day after treatment, Th2 and FEIR were lower than those in the control group, serum markers of airway remodeling were also significantly lower than those in the control group (all P <0.05) . Conclusion Astragalus injection can effectively improve the immune and airway remodeling in children with bronchial asthma, which has a good effect on the disease and the overall improvement of the body in children.